Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Use of omalizumab in the treatment of food allergy and anaphylaxis
Jay A. Lieberman
,
Mirna Chehade
Elliot and Roslyn Jaffe Food Allergy Institute
Environmental Medicine
Icahn School of Medicine at Mount Sinai
Institute for Exposomic Research
Medicine - Gastroenterology
Research output
:
Contribution to journal
›
Article
›
peer-review
63
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Use of omalizumab in the treatment of food allergy and anaphylaxis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Food Allergy Prevention
100%
Omalizumab
100%
Food-induced Anaphylaxis
100%
Food Allergy
42%
High Dose
14%
Clinical Trials
14%
Clinical Application
14%
Multicenter Trial
14%
Mechanism of Action
14%
Allergic Asthma
14%
Basophils
14%
Allergen
14%
Anaphylaxis
14%
Humanized
14%
Mast Cells
14%
Receptor Expression
14%
FDA-approved Drugs
14%
Immunotherapy Trials
14%
Anti-IgE Antibody
14%
Mast Cell Activation Syndrome
14%
Adjunct Therapy
14%
IgE Receptor
14%
Mediator Release
14%
Idiopathic Anaphylaxis
14%
Immunology and Microbiology
Anaphylaxis
100%
Food Allergy
100%
Omalizumab
100%
Immunotherapy
28%
Immunoglobulin E
28%
Mast Cell
28%
Drug Megadose
14%
Allergic Asthma
14%
Allergen
14%
Basophil
14%
Immunoglobulin E Antibody
14%
Mediator Release
14%
Monoclonal Anti-IgE
14%
Pharmacology, Toxicology and Pharmaceutical Science
Food Allergy
100%
Anaphylaxis
100%
Omalizumab
100%
Immunotherapy
28%
Allergic Asthma
14%
Immunoglobulin E
14%
Clinical Trial
14%
Immunoglobulin E Antibody
14%
Allergen
14%
Large Multicenter Trial
14%
Monoclonal Anti-IgE
14%
Immunoglobulin E Receptor
14%